Efinaconazole
![Ehealth DSI [Ehdsi V2.2.2-OR] Ehealth DSI – Master Value Set](http://data.docslib.org/img/264x/135084d885a0ce0d8ef8f9f83426c79a.webp)
Top View
- Ciclopirox, Efinaconazole, Tavaborole Prior Authorization with Quantity Limit Criteria Program Summary
- Medication Coverage Policy
- Univerza V Ljubljani Fakulteta Za Farmacijo
- Supporting Information
- Jublia) Reference Number: CP.PMN.25 Effective Date: 08.01.16 Last Review Date: 02.21 Line of Business: Commercial, HIM, Medicaid Revision Log
- Antifungals of the Azole Type
- Topical Antifungal Therapy for Toenail Onychomycosis
- Challenges and Opportunities in the Management of Onychomycosis
- Previous Versions
- Treatment of Dermatophytosis in Elderly, Children, and Pregnant Women
- UC Davis Dermatology Online Journal
- Effect of Penetration Enhancers on Toenail Delivery of Efinaconazole
- PREVALENCE of NON-CYTOCHROME P450-MEDIATED METABOLISM in FDA APPROVED ORAL and INTRAVENOUS DRUGS: 2006 – 2015 Matthew A. Cern
- Efinaconazole for Fungal Nail Infections: a Review of the Clinical Effectiveness, Cost-Effectiveness, and Guidelines
- 2020.05.13.093922V1.Full.Pdf
- Antifungal Drugs for Onychomycosis: Efficacy, Safety, and Mechanisms of Action Theodore Rosen, MD*, and Linda F
- ONYCHOMYCOSIS and OTHER FUNGAL INFECTIONS a Review of Recent Developments for Efficacious Treatments
- SWITCH PATTERNS AMONG PATIENTS CLAIMING ANTIFUNGAL THERAPIES for ONYCHOMYCOSIS in CANADA Yang H¹, Kukaswadia A¹, Gaudet V², Sharma A³, Barbeau M² 1